Physician profile
Joel Lehrer
NPI 1720079106
$666.57
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $384 · 2020: $137 · 2021: $129 · 2022: $15.76.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $157.30 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $101.12 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $84.32 | 2019-2020 | |
| Adamas Pharmaceuticals, INC. | $54.48 | 2019-2021 | |
| Alexion Pharmaceuticals, INC. | $41.76 | 2019-2020 | |
| Avanir Pharmaceuticals, INC. | $39.10 | 2019 | |
| Lundbeck LLC | $26.66 | 2019-2020 | |
| Mallinckrodt Enterprises LLC | $16.83 | 2019 | |
| Arbor Pharmaceuticals, INC. | $15.76 | 2022 | |
| Bausch Health US, LLC | $15.26 | 2019 | |
| Genzyme Corporation | $15.18 | 2019 | |
| Neurocrine Biosciences, INC. | $15.00 | 2020 | |
| Upsher-Smith Laboratories LLC | $14.89 | 2021 | |
| Ucb, INC. | $14.69 | 2019 | |
| Optinose US, INC. | $13.75 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $13.64 | 2020 | |
| Acorda Therapeutics, INC | $13.63 | 2019 | |
| Jazz Pharmaceuticals INC. | $13.20 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joel Lehrer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.